News

Filter

Current filters:

Orfadin

1 to 9 of 13 results

SOBI increases revenues by 25%, boosted by a doubling of Orfadin sales

SOBI increases revenues by 25%, boosted by a doubling of Orfadin sales

30-10-2014

Biotech firm Swedish Orphan Biovitrum has announced total revenues of 665.9 million Swedish kronor ($99.8…

BiotechnologyBusiness FinanceOrfadinSobiSweden

Sobi revenues up 27% in 2nd-qtr 2014

Sobi revenues up 27% in 2nd-qtr 2014

18-07-2014

Biotech firm Swedish Orphan Biovitrum, announced total revenues of 662.5 million Swedish kronor ($97…

FinancialOrfadinPharmaceuticalSobiSwedish Orphan Biovitrum

SOBI assumes direct responsibility for rare disease drug Orfadin in the USA and Canada

SOBI assumes direct responsibility for rare disease drug Orfadin in the USA and Canada

01-04-2014

Biotech firm Swedish Orphan Biovitrum has assumed direct responsibility for the distribution of its proprietary…

BiotechnologyMarkets & MarketingNorthern EuropeOrfadinRare diseasesSobi

Sobi terminates deal with Rare Disease Therapeutics for Orfadin distribution

Sobi terminates deal with Rare Disease Therapeutics for Orfadin distribution

20-12-2013

Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI) has terminated its distributor agreement with…

BiotechnologyLegalLicensingNorthern EuropeOrfadinRare Disease TherapeuticsSobi

SOBI reveals strong sales in third quarter

SOBI reveals strong sales in third quarter

30-10-2013

Swedish Orphan Biovitrum has published its third quarter results revealing that total revenues were 517.3…

EuropeFinancialKineretOrfadinPharmaceuticalSobi

SOBI files for Orfadin oral suspension with EMA

22-08-2013

Swedish Orphan Biovitrum (STO: SOBI) said this morning (August 22) that the company's application for…

EuropeOrfadinPharmaceuticalRare diseasesRegulationSwedish Orphan Biovitrum

Synosia initiates proof-of-concept nitisinone study in RLS

22-12-2008

Switzerland's Synosia Therapeutics has initiated a proof-of-concept trial to evaluate the efficacy and…

DopamineDopamine HydrochlorideNitisinoneOrfadin

Synosia initiates Ph IIa trial of PD drug

14-07-2008

Switzerland's Synosia Therapeutics has initiated a proof-of-mechanism trial to evaluate the efficacy…

DopamineDopamine HydrochlorideNitisinoneOrfadin

1 to 9 of 13 results

COMPANY SPOTLIGHT

Menarini

Back to top